Shopping Cart 0
Cart Subtotal
AED 0

Musculoskeletal Disorders Drugs MGR 2017

Bundle Purchase

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 14680

Access to Printed Report; No Soft Copy
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : Printed Publication/ Book by Post

Hard Copy License
AED 14680

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 22020

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

CD-Rom
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 29360

Details

The musculoskeletal system drugs market covers medications used in the treatment of musculoskeletal diseases such as arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus, and other musculoskeletal diseases. Some of the major drugs in the market include Humira, Remicade, Brineura, Tymlos (abaloparatide), and Enbrel.

The global musculoskeletal disorders drugs market was estimated to be around $121 billion as of 2016. The musculoskeletal disorders drugs market made up around 11% of the overall pharmaceuticals market in 2016. The musculoskeletal disorders drugs market was the fourth largest market in the global pharmaceutical market in 2016.

New Product Approvals

The product approvals of new musculoskeletal drugs by regulatory bodies is a significant positive trend being witnessed by the market in recent years. For instance, in April 2017, BioMarin received FDA approval for its Brineura (cerliponase alfa) drug that is used for the treatment of late infantile neuronal ceroid lipofuscinosis type 2. In May 2017, Sanofi received FDA approval for its Kevzara drug that is used in the treatment of active rheumatoid arthritis.

The Musculoskeletal Disorders Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global musculoskeletal disorders drugs sector.

Reasons to Purchase

Outperform competitors using accurate up to date demand-side dynamics information.

Identify growth segments for investment.

Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

Create regional and country strategies on the basis of local data and analysis.

Stay abreast of the latest customer and market research findings

Benchmark performance against key competitors.

Develop strategies based on likely future developments.

Utilize the relationships between key data sets for superior strategizing.

Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Gain a global perspective on the development of the market.

Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:

Where is the largest and fastest growing market for the musculoskeletal disorders drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The musculoskeletal disorders drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.

The market characteristics section of the report defines and explains the market.

The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down market into sub markets.

The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

The musculoskeletal disorders drugs market section of the report gives context. It compares the Musculoskeletal Disorders drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.

The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.

Scope

Markets Covered: Rheumatoid Arthritis, Muscle Relaxants, Others

Companies Mentioned: AbbVie, Amgen, Johnson & Johnson, F. Hoffmann-La Roche Ltd, and Pfizer Inc.

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

READ MORE

Table Of Content

Scope

1. Musculoskeletal Disorders Drugs Market Characteristics;

2. Musculoskeletal Disorders Drugs Market Size And Growth;

2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;

3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Musculoskeletal Disorders Drugs Market Customer Information;

5. Musculoskeletal Disorders Drugs Market Segmentation;

5.1. Global Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 5.2. Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Musculoskeletal Disorders Drugs Market Trends And Strategies;

6. Musculoskeletal Disorders Drugs Market Regional And Country Analysis;

6.1. Global Musculoskeletal Disorders Drugs Market, 2016, By Region; 6.2. Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region; 6.3. Musculoskeletal Disorders Drugs Market, 2016, By Country; 6.4. Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country;

7. Global Musculoskeletal Disorders Drugs Market Comparison With Macro Economic Factors;

7.1. Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, Global;

8. Musculoskeletal Disorders Drugs Market Comparison With Macro Economic Factors Across Countries;

8.1. Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, By Country;

9. Musculoskeletal Disorders Drugs Market Comparison With Industry Metrics;

9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Musculoskeletal Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Musculoskeletal Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Rheumatoid Arthritis, 2015, By Country; 9.10. Global Number Of General Practitioners 2016, By Country; 9.11. Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;

10. Asia-Pacific Musculoskeletal Disorders Drugs Market;

10.1.1. Asia-Pacific Musculoskeletal Disorders Drugs Market Overview; 10.1.2. Asia-Pacific Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 10.1.3. Asia-Pacific Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.2. Asia-Pacific Musculoskeletal Disorders Drugs Market: Country Analysis; 10.3. China Musculoskeletal Disorders Drugs Market; 10.3.1. China Musculoskeletal Disorders Drugs Market Overview; 10.3.2. China Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 10.3.3. China Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 10.3.4. China Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.3.5. China Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 10.4. India Musculoskeletal Disorders Drugs Market; 10.4.1. India Musculoskeletal Disorders Drugs Market Overview; 10.4.2. India Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 10.4.3. India Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 10.4.4. India Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.4.5. India Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 10.5. Japan Musculoskeletal Disorders Drugs Market; 10.5.1. Japan Musculoskeletal Disorders Drugs Market Overview; 10.5.2. Japan Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 10.5.3. Japan Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 10.5.4. Japan Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.5.5. Japan Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 10.6. Australia Musculoskeletal Disorders Drugs Market; 10.6.1. Australia Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 10.6.2. Australia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 10.6.3. Australia Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.6.4. Australia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020;

11. Western Europe Musculoskeletal Disorders Drugs Market;

11.1.1. Western Europe Musculoskeletal Disorders Drugs Market Overview; 11.1.2. Western Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.1.3. Western Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.1.4. Western Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.2. Western Europe Musculoskeletal Disorders Drugs Market: Country Analysis; 11.3. UK Musculoskeletal Disorders Drugs Market; 11.3.1. UK Musculoskeletal Disorders Drugs Market Overview; 11.3.2. UK Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.3.3. UK Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.3.4. UK Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.3.5. UK Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 11.4. Germany Musculoskeletal Disorders Drugs Market; 11.4.1. Germany Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.4.2. Germany Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.4.3. Germany Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.4.4 Germany Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 11.5 France Musculoskeletal Disorders Drugs Market; 11.5.1 France Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.5.2 France Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.5.3 France Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.5.4 France Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 11.6. Italy Musculoskeletal Disorders Drugs Market; 11.6.1. Italy Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.6.2. Italy Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.6.3. Italy Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.6.4. Italy Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 11.7. Spain Musculoskeletal Disorders Drugs Market; 11.7.1. Spain Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.7.2. Spain Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.7.3. Spain Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.7.4. Spain Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020;

12. Eastern Europe Musculoskeletal Disorders Drugs Market;

12.1.1. Eastern Europe Musculoskeletal Disorders Drugs Market Overview; 12.1.2. Eastern Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 12.1.3. Eastern Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 12.1.4 Eastern Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 12.2. Eastern Europe Musculoskeletal Disorders Drugs Market: Country Analysis; 12.3. Russia Musculoskeletal Disorders Drugs Market; 12.3.1. Russia Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 12.3.2. Russia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 12.3.3. Russia Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 12.3.4. Russia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020;

13. North America Musculoskeletal Disorders Drugs Market;

13.1.1. North America Musculoskeletal Disorders Drugs Market Overview; 13.1.2. North America Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 13.1.3. North America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 13.1.4. North America Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 13.2. North America Musculoskeletal Disorders Drugs Market: Country Analysis; 13.3. USA Musculoskeletal Disorders Drugs Market; 13.3.1. USA Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 13.3.2. USA Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 13.3.3 USA Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 13.3.4. USA Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020;

14. South America Musculoskeletal Disorders Drugs Market;

14.1.1. South America Musculoskeletal Disorders Drugs Market Overview; 14.1.2. South America Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 14.1.3. South America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 14.1.4. South America Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 14.2. South America Musculoskeletal Disorders Drugs Market: Country Analysis; 14.3. Brazil Musculoskeletal Disorders Drugs Market; 14.3.1. Brazil Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 14.3.2. Brazil Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 14.3.3. Brazil Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 14.3.4. Brazil Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020;

15. Middle East Musculoskeletal Disorders Drugs Market;

15.1.1. Middle East Musculoskeletal Disorders Drugs Market Overview; 15.1.2. Middle East Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 15.1.3. Middle East Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 15.1.4. Middle East Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ;

16. Africa Musculoskeletal Disorders Drugs Market;

16.1.1. Africa Musculoskeletal Disorders Drugs Market Overview; 16.1.1. Africa Musculoskeletal Disorders Drugs Market Overview; 16.1.2. Africa Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 16.1.3. Africa Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 16.1.4. Africa Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ;

17. Musculoskeletal Disorders Drugs Market Competitive Landscape;

17.1. Company Profiles; 17.2. Abbvie; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Amgen; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Johnson & Johnson; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. F. Hoffmann-La Roche Ltd; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Pfizer Inc.; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Musculoskeletal Disorders Drugs Market;

19. Market Background: Pharmaceutical Drugs Market;

19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;

21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer


List Of Figure

Table 1: Global Musculoskeletal Disorders Drugs Historic Market Growth

Table 2: Global Musculoskeletal Disorders Drugs Forecast Market Growth

Table 3: Musculoskeletal Disorders Drugs Market Segmentation

Table 4: Global Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 5: Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment

Table 6: Global Musculoskeletal Disorders Drugs Market, 2016, By Region

Table 7: Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 8: Musculoskeletal Disorders Drugs Market, 2016, By Country

Table 9: Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 10: Global Pharmaceutical Market Segments, 2016, By Region

Table 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region

Table 12: Global Pharmaceutical Market Segments, 2016, By Country

Table 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country

Table 14: Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, Global

Table 15: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, Global

Table 16: Musculoskeletal Disorders Drugs Market Comparison With Macro Economic Factors Across Countries

Table 17: Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, By Country

Table 18: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, By Country

Table 19: Global Number Of Pharmacists, 2016, By Country

Table 20: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Table 21: Global Number Of Pharma Enterprises, 2016, By Country

Table 22: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Table 23: Global Average Spending On R&D/Product Development, 2016, By Country

Table 24: Global Musculoskeletal Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Table 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 26: Global Musculoskeletal Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 27: Prevalent Cases Of Rheumatoid Arthritis, 2015, By Country

Table 28: Global Number Of General Practitioners 2016, By Country

Table 29: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country

Table 30: Asia-Pacific Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 31: Asia-Pacific Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 32: Asia-Pacific Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 33: China Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 34: China Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 35: China Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 36: China Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 37: China Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 38: India Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 39: India Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 40: India Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 41: India Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 42: India Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 43: Japan Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 44: Japan Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 45: Japan Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 46: Japan Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 47: Japan Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 48: Australia Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 49: Australia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 50: Australia Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 51: Australia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 52: Australia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 53: Western Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 54: Western Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 55: Western Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 56: UK Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 57: UK Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 58: UK Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 59: UK Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 60: UK Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 61: Germany Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 62: Germany Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 63: Germany Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 64: Germany Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 65: Germany Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 66: France Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 67: France Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 68: France Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 69: France Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 70: France Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 71: Italy Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 72: Italy Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 73: Italy Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 74: Italy Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 75: Italy Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 76: Spain Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 77: Spain Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 78: Spain Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 79: Spain Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 80: Spain Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 81: Eastern Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 82: Eastern Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 83: Eastern Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 84: Russia Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 85: Russia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 86: Russia Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 87: Russia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 88: Russia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 89: North America Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 90: North America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 91: North America Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 92: USA Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 93: USA Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 94: USA Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 95: USA Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 96: USA Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 97: South America Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 98: South America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 99: South America Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 100: Brazil Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 101: Brazil Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 102: Brazil Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 103: Brazil Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 104: Brazil Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 105: Middle East Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 106: Middle East Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 107: Middle East Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 108: Africa Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 109: Africa Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 110: Africa Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 111: Abbvie Financial Performance

Table 112: Amgen Financial Performance

Table 113: Johnson & Johnson Financial Performance

Table 114: F. Hoffmann-La Roche Ltd Financial Performance

Table 115: Pfizer Inc. Financial Performance

Table 116: Pharmaceutical Drugs Market Historic Growth

Table 117: Pharmaceutical Drugs Market Forecast Growth

Table 118: Global Pharmaceutical Drugs Market, 2016, By Region

Table 119: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 120: Pharmaceutical Drugs Market, 2016, By Country

Table 121: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 122: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Table 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Table 124: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Table 125: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Table 126: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Table 127: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Table 128: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Table 129: Pharmaceuticals Industry Financial Margins


List Of Table

Figure 1: Global Musculoskeletal Disorders Drugs Historic Market Growth

Figure 2: Global Musculoskeletal Disorders Drugs Forecast Market Growth

Figure 3: Musculoskeletal Disorders Drugs Market Segmentation

Figure 4: Global Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 5: Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment

Figure 6: Global Musculoskeletal Disorders Drugs Market, 2016, By Region

Figure 7: Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 8: Musculoskeletal Disorders Drugs Market, 2016, By Country

Figure 9: Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 10: Global Pharmaceutical Market Segments, 2016, By Region

Figure 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region

Figure 12: Global Pharmaceutical Market Segments, 2016, By Country

Figure 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country

Figure 14: Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, Global

Figure 15: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, Global

Figure 16: Musculoskeletal Disorders Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 17: Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, By Country

Figure 18: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, By Country

Figure 19: Global Number Of Pharmacists, 2016, By Country

Figure 20: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Figure 21: Global Number Of Pharma Enterprises, 2016, By Country

Figure 22: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Figure 23: Global Average Spending On R&D/Product Development, 2016, By Country

Figure 24: Global Musculoskeletal Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Figure 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 26: Global Musculoskeletal Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 27: Prevalent Cases Of Rheumatoid Arthritis, 2015, By Country

Figure 28: Global Number Of General Practitioners 2016, By Country

Figure 29: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country

Figure 30: Asia-Pacific Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 31: Asia-Pacific Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 32: Asia-Pacific Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 33: China Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 34: China Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 35: China Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 36: China Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 37: China Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 38: India Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 39: India Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 40: India Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 41: India Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 42: India Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 43: Japan Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 44: Japan Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 45: Japan Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 46: Japan Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 47: Japan Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 48: Australia Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 49: Australia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 50: Australia Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 51: Australia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 52: Australia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 53: Western Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 54: Western Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 55: Western Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 56: UK Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 57: UK Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 58: UK Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 59: UK Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 60: UK Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 61: Germany Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 62: Germany Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 63: Germany Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 64: Germany Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 65: Germany Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 66: France Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 67: France Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 68: France Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 69: France Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 70: France Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 71: Italy Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 72: Italy Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 73: Italy Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 74: Italy Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 75: Italy Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 76: Spain Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 77: Spain Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 78: Spain Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 79: Spain Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 80: Spain Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 81: Eastern Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 82: Eastern Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 83: Eastern Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 84: Russia Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 85: Russia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 86: Russia Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 87: Russia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 88: Russia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 89: North America Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 90: North America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 91: North America Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 92: USA Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 93: USA Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 94: USA Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 95: USA Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 96: USA Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 97: South America Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 98: South America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 99: South America Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 100: Brazil Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 101: Brazil Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 102: Brazil Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 103: Brazil Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 104: Brazil Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 105: Middle East Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 106: Middle East Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 107: Middle East Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 108: Africa Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 109: Africa Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 110: Africa Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 111: Abbvie Financial Performance

Figure 112: Amgen Financial Performance

Figure 113: Johnson & Johnson Financial Performance

Figure 114: F. Hoffmann-La Roche Ltd Financial Performance

Figure 115: Pfizer Inc. Financial Performance

Figure 116: Pharmaceutical Drugs Market Historic Growth

Figure 117: Pharmaceutical Drugs Market Forecast Growth

Figure 118: Global Pharmaceutical Drugs Market, 2016, By Region

Figure 119: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 120: Pharmaceutical Drugs Market, 2016, By Country

Figure 121: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 122: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Figure 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Figure 124: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Figure 125: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Figure 126: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 127: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Figure 128: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Figure 129: Pharmaceuticals Industry Financial Margins

Licence Rights

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Drugs For Rheumatoid Arthritis, Muscle Relaxants, Others


Companies

AbbVie, Amgen, Johnson & Johnson, F. Hoffmann-La Roche Ltd, and Pfizer Inc.

Company Profile

Company Profile Title

The musculoskeletal system drugs market covers medications used in the treatment of musculoskeletal diseases such as arthritis, osteoporosis, osteomalacia, carpal tunnel syndrome, tendonitis, rotator cuff tear, muscular dystrophy, myasthenia gravis, lupus erythematosus, and other musculoskeletal diseases. Some of the major drugs in the market include Humira, Remicade, Brineura, Tymlos (abaloparatide), and Enbrel.

The global musculoskeletal disorders drugs market was estimated to be around $121 billion as of 2016. The musculoskeletal disorders drugs market made up around 11% of the overall pharmaceuticals market in 2016. The musculoskeletal disorders drugs market was the fourth largest market in the global pharmaceutical market in 2016.

New Product Approvals

The product approvals of new musculoskeletal drugs by regulatory bodies is a significant positive trend being witnessed by the market in recent years. For instance, in April 2017, BioMarin received FDA approval for its Brineura (cerliponase alfa) drug that is used for the treatment of late infantile neuronal ceroid lipofuscinosis type 2. In May 2017, Sanofi received FDA approval for its Kevzara drug that is used in the treatment of active rheumatoid arthritis.

The Musculoskeletal Disorders Drugs Market Global Report provides strategists, marketers and senior management with the critical information they need to assess the global musculoskeletal disorders drugs sector.

Reasons to Purchase

Outperform competitors using accurate up to date demand-side dynamics information.

Identify growth segments for investment.

Facilitate decision making on the basis of historic and forecast data and the drivers and restraints on the market.

Create regional and country strategies on the basis of local data and analysis.

Stay abreast of the latest customer and market research findings

Benchmark performance against key competitors.

Develop strategies based on likely future developments.

Utilize the relationships between key data sets for superior strategizing.

Suitable for supporting your internal and external presentations with reliable high quality data and analysis

Gain a global perspective on the development of the market.

Report will be updated with the latest data and delivered to you within 3-5 working days of order.

Description:

Where is the largest and fastest growing market for the musculoskeletal disorders drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The musculoskeletal disorders drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider pharmaceutical drugs market, and compares it with other markets.

The market characteristics section of the report defines and explains the market.

The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.

Market segmentations break down market into sub markets.

The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.

Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.

The musculoskeletal disorders drugs market section of the report gives context. It compares the Musculoskeletal Disorders drugs market with other segments of the pharmaceutical drugs market by size and growth, historic and forecast. It analyses Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.

The industry metrics section looks at critical drivers including patient numbers (epidemiology) hospital beds and specialist physicians while the macro-economic section looks at the market in relation to the overall economy.

Scope

Markets Covered: Rheumatoid Arthritis, Muscle Relaxants, Others

Companies Mentioned: AbbVie, Amgen, Johnson & Johnson, F. Hoffmann-La Roche Ltd, and Pfizer Inc.

Countries: Brazil, China, France, Germany, India, Italy, Japan, Spain, Russia, UK, USA and Australia.

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East And Africa

Time series: Five years historic and forecast.

Data: Ratios of market size and growth to related markets, GDP, Expenditure Per Capita, The Musculoskeletal Disorders Drugs Indicators Comparison.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

READ MORE

Scope

1. Musculoskeletal Disorders Drugs Market Characteristics;

2. Musculoskeletal Disorders Drugs Market Size And Growth;

2.1. Historic Market Growth; 2.1.1. Drivers Of The Market; 2.1.2. Restraints On The Market; 2.2. Forecast Market Growth; 2.2.1. Drivers Of The Market; 2.2.2. Restraints On The Market;

3. Pestle Analysis;

3.1. Political; 3.2. Economic; 3.3. Social; 3.4. Technological; 3.5. Legal; 3.6. Environmental;

4. Musculoskeletal Disorders Drugs Market Customer Information;

5. Musculoskeletal Disorders Drugs Market Segmentation;

5.1. Global Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 5.2. Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment; 5.3 Global Musculoskeletal Disorders Drugs Market Trends And Strategies;

6. Musculoskeletal Disorders Drugs Market Regional And Country Analysis;

6.1. Global Musculoskeletal Disorders Drugs Market, 2016, By Region; 6.2. Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region; 6.3. Musculoskeletal Disorders Drugs Market, 2016, By Country; 6.4. Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country; 6.5. Global Pharmaceutical Market Segments, 2016, By Region; 6.6. Global Pharmaceutical Drugs Market Segments, 2016, By Region; 6.7. Global Pharmaceutical Market Segments, 2016, By Country; 6.8. Global Pharmaceutical Drugs Market Segments, 2016, By Country;

7. Global Musculoskeletal Disorders Drugs Market Comparison With Macro Economic Factors;

7.1. Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, Global; 7.2. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, Global;

8. Musculoskeletal Disorders Drugs Market Comparison With Macro Economic Factors Across Countries;

8.1. Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, By Country; 8.2. Per Capita Average Musculoskeletal Disorders Drugs Expenditure, By Country;

9. Musculoskeletal Disorders Drugs Market Comparison With Industry Metrics;

9.1. Global Number Of Pharmacists, 2016, By Country; 9.2. Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country; 9.3. Global Number Of Pharma Enterprises, 2016, By Country; 9.4. Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country; 9.5. Global Average Spending On R&D/Product Development, 2016, By Country; 9.6. Global Musculoskeletal Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country; 9.7. Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.8. Global Musculoskeletal Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country; 9.9. Prevalent Cases Of Rheumatoid Arthritis, 2015, By Country; 9.10. Global Number Of General Practitioners 2016, By Country; 9.11. Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country;

10. Asia-Pacific Musculoskeletal Disorders Drugs Market;

10.1.1. Asia-Pacific Musculoskeletal Disorders Drugs Market Overview; 10.1.2. Asia-Pacific Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 10.1.3. Asia-Pacific Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 10.1.4. Asia-Pacific Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.2. Asia-Pacific Musculoskeletal Disorders Drugs Market: Country Analysis; 10.3. China Musculoskeletal Disorders Drugs Market; 10.3.1. China Musculoskeletal Disorders Drugs Market Overview; 10.3.2. China Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 10.3.3. China Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 10.3.4. China Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.3.5. China Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 10.3.6. China Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 10.4. India Musculoskeletal Disorders Drugs Market; 10.4.1. India Musculoskeletal Disorders Drugs Market Overview; 10.4.2. India Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 10.4.3. India Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 10.4.4. India Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.4.5. India Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 10.4.6. India Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 10.5. Japan Musculoskeletal Disorders Drugs Market; 10.5.1. Japan Musculoskeletal Disorders Drugs Market Overview; 10.5.2. Japan Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 10.5.3. Japan Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 10.5.4. Japan Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.5.5. Japan Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 10.5.6. Japan Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 10.6. Australia Musculoskeletal Disorders Drugs Market; 10.6.1. Australia Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 10.6.2. Australia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 10.6.3. Australia Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 10.6.4. Australia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 10.6.5. Australia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020;

11. Western Europe Musculoskeletal Disorders Drugs Market;

11.1.1. Western Europe Musculoskeletal Disorders Drugs Market Overview; 11.1.2. Western Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.1.3. Western Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.1.4. Western Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.2. Western Europe Musculoskeletal Disorders Drugs Market: Country Analysis; 11.3. UK Musculoskeletal Disorders Drugs Market; 11.3.1. UK Musculoskeletal Disorders Drugs Market Overview; 11.3.2. UK Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.3.3. UK Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.3.4. UK Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.3.5. UK Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 11.3.6. UK Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 11.4. Germany Musculoskeletal Disorders Drugs Market; 11.4.1. Germany Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.4.2. Germany Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.4.3. Germany Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.4.4 Germany Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 11.4.5 Germany Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 11.5 France Musculoskeletal Disorders Drugs Market; 11.5.1 France Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.5.2 France Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.5.3 France Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.5.4 France Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 11.5.5 France Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 11.6. Italy Musculoskeletal Disorders Drugs Market; 11.6.1. Italy Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.6.2. Italy Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.6.3. Italy Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.6.4. Italy Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 11.6.5. Italy Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020; 11.7. Spain Musculoskeletal Disorders Drugs Market; 11.7.1. Spain Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 11.7.2. Spain Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 11.7.3. Spain Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 11.7.4. Spain Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 11.7.5. Spain Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020;

12. Eastern Europe Musculoskeletal Disorders Drugs Market;

12.1.1. Eastern Europe Musculoskeletal Disorders Drugs Market Overview; 12.1.2. Eastern Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 12.1.3. Eastern Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 12.1.4 Eastern Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 12.2. Eastern Europe Musculoskeletal Disorders Drugs Market: Country Analysis; 12.3. Russia Musculoskeletal Disorders Drugs Market; 12.3.1. Russia Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 12.3.2. Russia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 12.3.3. Russia Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 12.3.4. Russia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 12.3.5. Russia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020;

13. North America Musculoskeletal Disorders Drugs Market;

13.1.1. North America Musculoskeletal Disorders Drugs Market Overview; 13.1.2. North America Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 13.1.3. North America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 13.1.4. North America Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 13.2. North America Musculoskeletal Disorders Drugs Market: Country Analysis; 13.3. USA Musculoskeletal Disorders Drugs Market; 13.3.1. USA Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 13.3.2. USA Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 13.3.3 USA Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 13.3.4. USA Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 13.3.5. USA Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020;

14. South America Musculoskeletal Disorders Drugs Market;

14.1.1. South America Musculoskeletal Disorders Drugs Market Overview; 14.1.2. South America Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 14.1.3. South America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 14.1.4. South America Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 14.2. South America Musculoskeletal Disorders Drugs Market: Country Analysis; 14.3. Brazil Musculoskeletal Disorders Drugs Market; 14.3.1. Brazil Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 14.3.2. Brazil Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 14.3.3. Brazil Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ; 14.3.4. Brazil Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020; 14.3.5. Brazil Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020;

15. Middle East Musculoskeletal Disorders Drugs Market;

15.1.1. Middle East Musculoskeletal Disorders Drugs Market Overview; 15.1.2. Middle East Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 15.1.3. Middle East Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 15.1.4. Middle East Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ;

16. Africa Musculoskeletal Disorders Drugs Market;

16.1.1. Africa Musculoskeletal Disorders Drugs Market Overview; 16.1.1. Africa Musculoskeletal Disorders Drugs Market Overview; 16.1.2. Africa Musculoskeletal Disorders Drugs Historic Market, 2012-2016; 16.1.3. Africa Musculoskeletal Disorders Drugs Forecast Market, 2016-2020; 16.1.4. Africa Musculoskeletal Disorders Drugs Market, 2016, By Segment; Drugs For Rheumatoid Arthritis; Muscle Relaxants; Others ;

17. Musculoskeletal Disorders Drugs Market Competitive Landscape;

17.1. Company Profiles; 17.2. Abbvie; 17.2.1. Overview; 17.2.2. Products And Services; 17.2.3. Strategy; 17.2.4. Financial Performance; 17.3. Amgen; 17.3.1. Overview; 17.3.2. Products And Services; 17.3.3. Strategy; 17.3.4. Financial Performance; 17.4. Johnson & Johnson; 17.4.1. Overview; 17.4.2. Products And Services; 17.4.3. Strategy; 17.4.4. Financial Performance; 17.5. F. Hoffmann-La Roche Ltd; 17.5.1. Overview; 17.5.2. Products And Services; 17.5.3. Strategy; 17.5.4. Financial Performance; 17.6. Pfizer Inc.; 17.6.1. Overview; 17.6.2. Products And Services; 17.6.3. Strategy; 17.6.4. Financial Performance;

18. Key Mergers And Acquisitions In The Musculoskeletal Disorders Drugs Market;

19. Market Background: Pharmaceutical Drugs Market;

19.1.1. Pharmaceutical Drugs Market Characteristics; 19.1.2. Pharmaceutical Drugs Market Historic Growth; 19.1.2.1. Drivers Of The Market; 19.1.2.2. Restraints Of The Market; 19.1.3. Pharmaceutical Drugs Market Forecast Growth; 19.1.3.1. Drivers Of The Market; 19.1.3.2. Restraints Of The Market; 19.1.4. Pharmaceutical Drugs Trends And Strategies; 19.2. Pharmaceutical Drugs Market Regional And Country Analysis; 19.2.1. Global Pharmaceutical Drugs Market, 2016, By Region; 19.2.2. Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region; 19.2.3. Pharmaceutical Drugs Market, 2016, By Country; 19.2.4. Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country; 19.2.5. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment; 19.2.6. Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment; 19.3. Global Pharmaceutical Drugs Market Comparison With Macro Economic Factors; 19.3.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, Global; 19.3.2. Per Capita Average Pharmaceutical Drugs Expenditure, Global; 19.4. Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries; 19.4.1. Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country; 19.4.2. Per Capita Average Pharmaceutical Drugs Expenditure, By Country; 19.5. Key Mergers And Acquisitions In The Pharmaceutical Drugs Market;

20. Pharmaceuticals Industry Financial Margins;

21. Appendix;

21.1. NAICS Definitions Of Industry Covered In This Report; 21.2. Abbreviations; 21.3. Currencies; 21.4. Research Inquiries; 21.5. The Business Research Company; 21.6. Copyright And Disclaimer


List Of Figure

Table 1: Global Musculoskeletal Disorders Drugs Historic Market Growth

Table 2: Global Musculoskeletal Disorders Drugs Forecast Market Growth

Table 3: Musculoskeletal Disorders Drugs Market Segmentation

Table 4: Global Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 5: Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment

Table 6: Global Musculoskeletal Disorders Drugs Market, 2016, By Region

Table 7: Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 8: Musculoskeletal Disorders Drugs Market, 2016, By Country

Table 9: Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 10: Global Pharmaceutical Market Segments, 2016, By Region

Table 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region

Table 12: Global Pharmaceutical Market Segments, 2016, By Country

Table 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country

Table 14: Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, Global

Table 15: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, Global

Table 16: Musculoskeletal Disorders Drugs Market Comparison With Macro Economic Factors Across Countries

Table 17: Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, By Country

Table 18: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, By Country

Table 19: Global Number Of Pharmacists, 2016, By Country

Table 20: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Table 21: Global Number Of Pharma Enterprises, 2016, By Country

Table 22: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Table 23: Global Average Spending On R&D/Product Development, 2016, By Country

Table 24: Global Musculoskeletal Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Table 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 26: Global Musculoskeletal Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Table 27: Prevalent Cases Of Rheumatoid Arthritis, 2015, By Country

Table 28: Global Number Of General Practitioners 2016, By Country

Table 29: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country

Table 30: Asia-Pacific Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 31: Asia-Pacific Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 32: Asia-Pacific Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 33: China Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 34: China Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 35: China Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 36: China Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 37: China Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 38: India Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 39: India Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 40: India Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 41: India Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 42: India Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 43: Japan Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 44: Japan Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 45: Japan Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 46: Japan Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 47: Japan Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 48: Australia Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 49: Australia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 50: Australia Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 51: Australia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 52: Australia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 53: Western Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 54: Western Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 55: Western Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 56: UK Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 57: UK Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 58: UK Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 59: UK Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 60: UK Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 61: Germany Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 62: Germany Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 63: Germany Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 64: Germany Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 65: Germany Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 66: France Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 67: France Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 68: France Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 69: France Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 70: France Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 71: Italy Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 72: Italy Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 73: Italy Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 74: Italy Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 75: Italy Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 76: Spain Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 77: Spain Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 78: Spain Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 79: Spain Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 80: Spain Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 81: Eastern Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 82: Eastern Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 83: Eastern Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 84: Russia Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 85: Russia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 86: Russia Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 87: Russia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 88: Russia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 89: North America Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 90: North America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 91: North America Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 92: USA Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 93: USA Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 94: USA Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 95: USA Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 96: USA Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 97: South America Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 98: South America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 99: South America Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 100: Brazil Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 101: Brazil Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 102: Brazil Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 103: Brazil Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Table 104: Brazil Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Table 105: Middle East Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 106: Middle East Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 107: Middle East Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 108: Africa Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Table 109: Africa Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Table 110: Africa Musculoskeletal Disorders Drugs Market, 2016, By Segment

Table 111: Abbvie Financial Performance

Table 112: Amgen Financial Performance

Table 113: Johnson & Johnson Financial Performance

Table 114: F. Hoffmann-La Roche Ltd Financial Performance

Table 115: Pfizer Inc. Financial Performance

Table 116: Pharmaceutical Drugs Market Historic Growth

Table 117: Pharmaceutical Drugs Market Forecast Growth

Table 118: Global Pharmaceutical Drugs Market, 2016, By Region

Table 119: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Table 120: Pharmaceutical Drugs Market, 2016, By Country

Table 121: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Table 122: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Table 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Table 124: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Table 125: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Table 126: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Table 127: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Table 128: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Table 129: Pharmaceuticals Industry Financial Margins


List Of Table

Figure 1: Global Musculoskeletal Disorders Drugs Historic Market Growth

Figure 2: Global Musculoskeletal Disorders Drugs Forecast Market Growth

Figure 3: Musculoskeletal Disorders Drugs Market Segmentation

Figure 4: Global Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 5: Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Segment

Figure 6: Global Musculoskeletal Disorders Drugs Market, 2016, By Region

Figure 7: Global Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 8: Musculoskeletal Disorders Drugs Market, 2016, By Country

Figure 9: Musculoskeletal Disorders Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 10: Global Pharmaceutical Market Segments, 2016, By Region

Figure 11: Global Pharmaceutical Drugs Market Segments, 2016, By Region

Figure 12: Global Pharmaceutical Market Segments, 2016, By Country

Figure 13: Global Pharmaceutical Drugs Market Segments, 2016, By Country

Figure 14: Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, Global

Figure 15: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, Global

Figure 16: Musculoskeletal Disorders Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 17: Musculoskeletal Disorders Drugs Market Size, Percentage Of GDP, By Country

Figure 18: Per Capita Average Musculoskeletal Disorders Drugs Expenditure, By Country

Figure 19: Global Number Of Pharmacists, 2016, By Country

Figure 20: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharmacists, 2016, By Country

Figure 21: Global Number Of Pharma Enterprises, 2016, By Country

Figure 22: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of Pharma Enterprises, 2016, By Country

Figure 23: Global Average Spending On R&D/Product Development, 2016, By Country

Figure 24: Global Musculoskeletal Disorders Drugs Market Revenue Versus Average Spending On R&D/Product Development, 2016, By Country

Figure 25: Global Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 26: Global Musculoskeletal Disorders Drugs Market Revenue Versus Generic & Branded Sales Proportion By Country (Value), 2016, By Country

Figure 27: Prevalent Cases Of Rheumatoid Arthritis, 2015, By Country

Figure 28: Global Number Of General Practitioners 2016, By Country

Figure 29: Global Musculoskeletal Disorders Drugs Market Revenue Versus Number Of General Practitioners, 2016, By Country

Figure 30: Asia-Pacific Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 31: Asia-Pacific Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 32: Asia-Pacific Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 33: China Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 34: China Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 35: China Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 36: China Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 37: China Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 38: India Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 39: India Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 40: India Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 41: India Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 42: India Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 43: Japan Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 44: Japan Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 45: Japan Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 46: Japan Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 47: Japan Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 48: Australia Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 49: Australia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 50: Australia Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 51: Australia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 52: Australia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 53: Western Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 54: Western Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 55: Western Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 56: UK Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 57: UK Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 58: UK Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 59: UK Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 60: UK Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 61: Germany Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 62: Germany Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 63: Germany Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 64: Germany Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 65: Germany Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 66: France Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 67: France Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 68: France Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 69: France Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 70: France Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 71: Italy Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 72: Italy Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 73: Italy Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 74: Italy Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 75: Italy Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 76: Spain Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 77: Spain Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 78: Spain Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 79: Spain Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 80: Spain Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 81: Eastern Europe Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 82: Eastern Europe Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 83: Eastern Europe Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 84: Russia Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 85: Russia Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 86: Russia Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 87: Russia Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 88: Russia Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 89: North America Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 90: North America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 91: North America Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 92: USA Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 93: USA Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 94: USA Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 95: USA Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 96: USA Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 97: South America Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 98: South America Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 99: South America Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 100: Brazil Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 101: Brazil Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 102: Brazil Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 103: Brazil Musculoskeletal Disorders Drugs Percentage Of GDP, 2012-2020

Figure 104: Brazil Per Capita Average Musculoskeletal Disorders Drugs Expenditure, 2012-2020

Figure 105: Middle East Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 106: Middle East Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 107: Middle East Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 108: Africa Musculoskeletal Disorders Drugs Historic Market, 2012-2016

Figure 109: Africa Musculoskeletal Disorders Drugs Forecast Market, 2016-2020

Figure 110: Africa Musculoskeletal Disorders Drugs Market, 2016, By Segment

Figure 111: Abbvie Financial Performance

Figure 112: Amgen Financial Performance

Figure 113: Johnson & Johnson Financial Performance

Figure 114: F. Hoffmann-La Roche Ltd Financial Performance

Figure 115: Pfizer Inc. Financial Performance

Figure 116: Pharmaceutical Drugs Market Historic Growth

Figure 117: Pharmaceutical Drugs Market Forecast Growth

Figure 118: Global Pharmaceutical Drugs Market, 2016, By Region

Figure 119: Global Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Region

Figure 120: Pharmaceutical Drugs Market, 2016, By Country

Figure 121: Pharmaceutical Drugs Market, 2012-2020, Historic And Forecast, By Country

Figure 122: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Segment

Figure 123: Global Pharmaceutical Drugs Market, Growth And Market Share Comparison, By Country And Segment

Figure 124: Pharmaceutical Drugs Market Size, Percentage Of GDP, Global

Figure 125: Per Capita Average Pharmaceutical Drugs Expenditure, Global

Figure 126: Pharmaceutical Drugs Market Comparison With Macro Economic Factors Across Countries

Figure 127: Pharmaceutical Drugs Market Size, Percentage Of GDP, By Country

Figure 128: Per Capita Average Pharmaceutical Drugs Expenditure, By Country

Figure 129: Pharmaceuticals Industry Financial Margins

  • Single User License (for access by one person)
  • Site License (for access of one office location of a company)
  • Corporate License (allow access by all staff of the company)
To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Drugs For Rheumatoid Arthritis, Muscle Relaxants, Others


Companies

AbbVie, Amgen, Johnson & Johnson, F. Hoffmann-La Roche Ltd, and Pfizer Inc.